Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMO for Newly-diagnosed PCNSL
NCT05549284Phase 2Recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Academy of Military Medical Sciences. Primary endpoints: Objective Response Rate at 2 years and Complete Response at 2 years. Started Jun 2022; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05549284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549284.